Clinical trials: IL13Ra
Phase 1, NK Cell
A Phase1 Clinical Trial Evaluating Locoregional Delivery Of Engineered NK Cells Containing IL13Ra And EGFvIII Chimeric Antigen Receptor (CAR), IL-21 Secretion And Deleted TGF-BetaR2 And NR3C1 In Recurrent Glioblastoma
To find the best method of administering NK cells in patients with recurrent glioblastoma.
- Conditions
- Phase 1, NK Cell, IL13Ra, EGFRvIII
- Trial name
- NCT07579208
- Testing
- NK Cells
- Where
- United States
- Volunteers
- 36 people
- Sponsor
- M.D. Anderson Cancer Center